Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Digoxin is associated wit… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction

Artikel i vetenskaplig tidskrift
Författare J. M. Zhou
J. Cao
X. J. Jin
J. Zhou
Z. Y. Chen
D. L. Xu
X. C. Yang
W. Dong
L. W. Li
Y. Y. Fan
L. Chen
Q. Q. Zhong
Michael Fu
K. Hu
J. B. Ge
Y. M. Lu
G. H. Zhang
Chen Li
H. M. Gu
M. Wei
L. L. Chen
J. Wang
Z. Y. Yang
H. G. Jin
X. L. Li
Z. Y. Qiao
Y. J. Yang
Y. L. Zhao
R. Jia
B. Hong
F. Yuan
J. F. Wang
J. Ma
Y. Xu
M. Wahafu
Q. Yu
C. Q. Wang
C. W. Ruan
H. G. Fu
X. B. Liu
X. Xu
S. P. Chen
Q. L. Liu
B. Shi
J. H. Xu
Publicerad i Esc Heart Failure
Volym 7
Nummer/häfte 1
Sidor 139-147
ISSN 2055-5822
Publiceringsår 2020
Publicerad vid Institutionen för medicin
Sidor 139-147
Språk en
Länkar dx.doi.org/10.1002/ehf2.12539
Ämnesord Digoxin, Heart failure, Atrial fibrillation, Prognosis, clinical characteristics, mortality, risk, guidelines, withdrawal, trial, Cardiovascular System & Cardiology
Ämneskategorier Kardiologi

Sammanfattning

Aims The aim of this study was to investigate the impact of digoxin use on the outcomes of patients with heart failure with reduced ejection fraction (HFrEF) and its possible interaction with atrial fibrillation or use of currently guideline-recommended treatments in the real world in China. Methods and results Patients hospitalized with HFrEF from 45 hospitals participating in the China National Heart Failure Registration Study (CN-HF) were enrolled to assess the all-cause mortality, HF mortality, all-cause re-hospitalization, and HF re-hospitalization associated with digoxin use. Eight hundred eighty-two eligible HFrEF patients in the CN-HF registry were included: 372 patients with digoxin and 510 patients without digoxin. Among them, 794 (90.0%) patients were followed up for the endpoint events, with a median follow-up of 28.6 months. Kaplan-Meier survival analysis showed that the all-cause mortality (P < 0.001) and all-cause re-hospitalization (P = 0.020) were significantly higher in digoxin group than non-digoxin group, while HF mortality (P = 0.232) and HF re-hospitalization (P = 0.098) were similar between the two groups. The adjusted Cox proportional-hazards regression analysis demonstrated that digoxin use remained as an independent risk factor for increased all-cause mortality [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.27-2.44; P = 0.001] and all-cause re-hospitalization (HR 1.27; 95% CI 1.03-1.57; P = 0.029) in HFrEF patients and the predictive value of digoxin for all-cause mortality irrespective of rhythm or in combination with other guideline-recommended therapies. Conclusions Digoxin use is independently associated with increased risk of all-cause mortality and all-cause re-hospitalization in HFrEF patients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?